Introduction:
Set to skyrocket from $367.1 billion in 2023 to $628 billion by 2032, the generic drug market is experiencing a boom! What's fueling this rapid expansion? A mix of factors: patent expirations, a rise in chronic diseases, and increased research investments. Expanding generic drug manufacturing is a boon for consumers and healthcare systems, making essential medications more affordable.
However, the path from “patent to patient” is challenging. This article delves into the complex lifecycle of generic drugs, examining how they transition from patented medications to market-ready alternatives. Let’s dive in!
Approaching The Patent Cliff: How Are We Bracing for Impact?
With the increasing demand for good-quality but affordable and accessible options, countries are adapting legislation to foster domestic drug development and boost the production of generic drugs.
After all, how did India become “Pharmacy of world”? It all began with the Patent Act of 1970, which cleverly shifted the focus from product patents to processes, enabling local firms to produce generics affordably. Then, signing the TRIPS Agreement in 1995 further aligned India with global intellectual property standards, encouraging innovation. Most recently, the 2021 Production-linked Incentive Scheme has given another boost, helping India meet the worldwide demand for affordable medicines and strengthening its status as a global pharmaceutical hub.
Similarly, markets worldwide are bracing themselves to capitalise on the opportunity to boost generic drug manufacturing as we approach the precipice of the patent cliff.
Crossing the Patent Threshold: The Shift to Generics
As the 20 to 25-year patent protection and market exclusivity ends, generic drug manufacturers worldwide are gearing up for a significant opportunity. The expiration of patents triggers increased competition, driving down prices and improving accessibility.
So, how does this transition from patent to generic occur?
To enter the market, these firms must demonstrate that their products are bioequivalent to the brand-name originals, ensuring they offer the same therapeutic benefits. This regulatory process, while stringent, is designed to be quicker and less resource-intensive than new drug approvals, facilitating a swift transition to more accessible and cost effective generic medications.
Regulatory Pathways for Generics
Bringing a generic drug to market involves a detailed and regulated process, ensuring safety, efficacy, and quality at every step. Strides Pharma leverages its expertise to excel in each phase:
1. Abbreviated New Drug Application (ANDA)
Generic drug manufacturers must file an Abbreviated New Drug Application (ANDA) with regulatory bodies like the FDA or EMA. This application focuses on proving that the generic product is bioequivalent to the innovator product without submitting new clinical trial data. It includes detailed information on the active ingredient, dosage form, strength, route of administration, and labelling.
Strides Pharma maintains a robust portfolio with 259 ANDAs and files 15+ new applications annually, demonstrating our capacity to meet stringent regulatory standards efficiently.
2. Bioequivalence Studies
Bioequivalence is a critical component of the ANDA, requiring the generic drug to match the brand-name drug in terms of the rate and extent of absorption.
At Strides Pharma, we formulate our products to ensure that bioequivalence criteria is met, underpinning the therapeutic equivalence of our generics to their branded counterparts.
3. Quality and Manufacturing Controls
Manufacturers must also prove they can consistently produce the drug according to high-quality standards. This involves detailed documentation of the manufacturing process, quality control procedures, and validation methods, ensuring the drug is reproducible and safe for public consumption.
Strides Pharma employs advanced automation to enhance efficiency and compliance in manufacturing complex formulations, including inhalers and time-release capsules. Our diverse production capabilities extend to various dosage forms, such as combi-packs, bi-layered tablets, and soft and hard-gel capsules.
4. Pricing, Marketing, and Distribution
This phase involves setting competitive prices, marketing to healthcare providers and consumers, and establishing a distribution network to enhance accessibility, ensuring broad access to affordable medications through partnerships with pharmacies and healthcare institutions.
The regulatory team at Strides Pharma excels in navigating complex approval processes, significantly speeding up the filing of new drug applications (NDAs). This ensures faster market access, bringing critical treatments to the market swiftly and efficiently.
The Generic Drug Playbook: Tackling the Toughest Challenges
1. Formulation Challenges
2. Testing and Regulatory Compliance
Generic manufacturers often struggle to replicate complex formulations involving proprietary technologies or patented excipients. Strides Pharma invests in advanced technologies like modified-release mechanisms and specialises in high-barrier products such as soft-gel capsules and topicals. This focus allows the company to navigate formulation challenges effectively and enter the market with unique, compliant generic options.
Rigorous testing to demonstrate bioequivalence and diverse global regulatory standards can delay generic drug approval and market entry.
With high-end manufacturing facilities in India, Italy and the US, Strides Pharma ensures compliance with international standards such as those set by the FDA, EMA, and WHO, enhancing its ability to scale production and reduce time-to-market.
Leveraging a hybrid R&D model, Strides Pharma combines in-house efforts with external collaborations to accelerate the development and approval of generics, particularly in key markets like Europe, Australia, South Africa, and Canada. This approach focuses on niche and complex generics, allowing for faster commercialization and less competitive market entry.
3. Intellectual Property Issues
Generic drug companies frequently encounter legal hurdles as brand-name companies seek to protect their patents. Even after a primary patent expires, secondary patents on processes or formulations can impede the entry of generic versions. Additionally, in the U.S., certain FDA-granted exclusivities, such as orphan drug exclusivity or pediatric exclusivity, can further delay the introduction of generics even beyond the original patent's expiry. Strides Pharma employs a proactive IP management strategy, engaging closely with regulatory bodies to navigate complex IP landscapes and minimise approval delays.
4. Market Dynamics
a) Price Competition
Once a patent expires, multiple manufacturers can produce generic versions of the drug, leading to a steep price drop due to heightened competition. Strides Pharma focuses on developing niche products with fewer competitors in the market. This strategic focus on niche, low-competition, high-barrier products like modified-release formulations and complex dosage forms helps maintain healthier margins.
b) Supply Chain Management
Scaling production to meet global demand efficiently requires a robust and responsive supply chain. Strides has developed strong partnerships with raw material suppliers and leverages its global manufacturing footprint with state-of-the-art facilities in India, Italy and the US. Additionally, Strides' supply chain automation and data governance investment enhances production efficiency and ensures consistent product availability across markets.
c) Market Penetration and Accessibility
Entering new markets and ensuring product accessibility can be hindered by regulatory barriers, local competition, and distribution challenges. Strides leverages robust marketing and distribution partnerships worldwide, which help navigate local regulatory landscapes and speed up market penetration. For example, Strides secured a long-term supply contract in Australia with Arrotex, Australia’s largest generic pharmaceutical and private label OTC business, solidifying its market presence and ensuring extensive distribution.
Conclusion:
The expiration of patents presents opportunities and challenges in generic drug manufacturing. Strides Pharma excels in adapting to market shifts and regulatory changes, efficiently launching generics to sustain competitive growth. Explore how partnering with Strides Pharma can advance your operations. Contact us today.
Click here to get in touch ! www.synergice.co
Key Takeaway Points:
References